Jane Street’s Fennec Pharmaceuticals FENC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.51M Buy
+233,877
New +$1.91M ﹤0.01% 4778
2026
Q1
Sell
-24,044
Closed -$185K 11983
2025
Q4
$185K Sell
24,044
-48,587
-67% -$399K ﹤0.01% 9792
2025
Q3
$680K Buy
72,631
+22,642
+45% +$196K ﹤0.01% 7170
2025
Q2
$415K Buy
49,989
+35,271
+240% +$241K ﹤0.01% 7278
2025
Q1
$89.6K Buy
+14,718
New +$94.5K ﹤0.01% 8860
2024
Q4
Sell
-19,339
Closed -$96.7K 9737
2024
Q3
$96.7K Sell
19,339
-465
-2% -$2.69K ﹤0.01% 9000
2024
Q2
$121K Buy
19,804
+4,250
+27% +$35.3K ﹤0.01% 8661
2024
Q1
$173K Buy
+15,554
New +$156K ﹤0.01% 8267
2023
Q2
Sell
-88,240
Closed -$734K 8922
2023
Q1
$734K Buy
88,240
+62,374
+241% +$579K ﹤0.01% 5617
2022
Q4
$248K Buy
25,866
+11,359
+78% +$101K ﹤0.01% 7332
2022
Q3
$118K Buy
+14,507
New +$99.6K ﹤0.01% 8558
2021
Q3
Sell
-24,278
Closed -$177K 10154
2021
Q2
$177K Buy
+24,278
New +$162K ﹤0.01% 8919
2020
Q3
Sell
-19,896
Closed -$166K 7360
2020
Q2
$166K Buy
+19,896
New +$148K ﹤0.01% 6485

Other funds holding FENC

Jane Street's FENC Position: Q2 2026 in Review

Jane Street opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 233,877 shares worth $2.51M. The stake represents ﹤0.01% of the portfolio and ranks #4778 among its holdings. This is a return to the name: Jane Street previously reported a position in FENC as recently as Q4 2025.

Jane Street first reported a position in FENC in Q2 2020 and has held it in 13 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Jane Street held 233,877 shares of Fennec Pharmaceuticals worth $2.51M as of Q2 2026.
  • Fennec Pharmaceuticals was a new Jane Street position in Q2 2026.
  • Fennec Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #4778 holding.
  • Jane Street first reported a position in Fennec Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.